Orencia (abatacept)

April 3, 2020April 3, 2020

Certain Vaccines in Children with Polyarticular JIA Maintain Effectiveness on Orencia, Study Finds

News

Young children with polyarticular juvenile idiopathic arthritis (pJIA) maintained effective vaccination against diphtheria and tetanus even after starting treatment with Orencia (abatecept) for up to two years, according to a ... Read more

May 14, 2019May 14, 2019

Orencia Safe, Effective for Children with Polyarticular JIA, Phase 3 Trial in Japan Confirms

News

Treatment with Orencia (abatacept) is well-tolerated and effective in managing disease activity in children with polyarticular juvenile idiopathic arthritis (JIA), according to results from a Phase 3 clinical trial conducted ... Read more

April 2, 2019April 2, 2019

Treatment Failure, Adverse Reactions in JIA Patients Potentially Linked to Antibodies Against Biologic Agents, Study Suggests

News

Approximately 17% of juvenile idiopathic arthritis (JIA) patients treated with biologic agents develop anti-drug antibodies (ADAbs) that can be associated with treatment failure and adverse events, a review study shows. ... Read more